Cargando…
Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review)
On a global scale, the incidence and mortality rates of lung cancer are gradually increasing year by year. A number of bad habits and environmental factors are associated with lung cancer, including smoking, second-hand smoke exposure, occupational exposure, respiratory diseases and genetics. At pre...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851127/ https://www.ncbi.nlm.nih.gov/pubmed/36601768 http://dx.doi.org/10.3892/ijo.2023.5474 |
_version_ | 1784872344106303488 |
---|---|
author | Wang, Qian Zeng, Anqi Zhu, Min Song, Linjiang |
author_facet | Wang, Qian Zeng, Anqi Zhu, Min Song, Linjiang |
author_sort | Wang, Qian |
collection | PubMed |
description | On a global scale, the incidence and mortality rates of lung cancer are gradually increasing year by year. A number of bad habits and environmental factors are associated with lung cancer, including smoking, second-hand smoke exposure, occupational exposure, respiratory diseases and genetics. At present, low-dose spiral computed tomography is routinely the first choice in the diagnosis of lung cancer. However, pathological examination is still the gold standard for the diagnosis of lung cancer. Based on the classification and stage of the cancer, treatment options such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy are available. The activation of the EGFR pathway can promote the survival and proliferation of tumor cells, and the VEGF pathway can promote the formation of blood vessels, thereby promoting tumor growth. In non-small cell lung cancer (NSCLC) with EGFR mutation, EGFR activation can promote tumor growth by promoting VEGF upregulation through a hypoxia-independent mechanism. The upregulation of VEGF can make tumor cells resistant to EGFR inhibitors. In addition, the expression of the VEGF signal is also affected by other factors. Therefore, the use of a single EGFR inhibitor cannot completely inhibit the expression of the VEGF signal. In order to overcome this problem, the combination of VEGF inhibitors and EGFR inhibitors has become the method of choice. Dual inhibition can not only overcome the resistance of tumor cells to EGFR inhibitors, but also significantly increase the progression-free survival time of patients with NSCLC. The present review discusses the associations between the EGFR and VEGF pathways, and the characteristics of dual inhibition of the EGFR-VEGF pathway. |
format | Online Article Text |
id | pubmed-9851127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-98511272023-02-03 Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) Wang, Qian Zeng, Anqi Zhu, Min Song, Linjiang Int J Oncol Articles On a global scale, the incidence and mortality rates of lung cancer are gradually increasing year by year. A number of bad habits and environmental factors are associated with lung cancer, including smoking, second-hand smoke exposure, occupational exposure, respiratory diseases and genetics. At present, low-dose spiral computed tomography is routinely the first choice in the diagnosis of lung cancer. However, pathological examination is still the gold standard for the diagnosis of lung cancer. Based on the classification and stage of the cancer, treatment options such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy are available. The activation of the EGFR pathway can promote the survival and proliferation of tumor cells, and the VEGF pathway can promote the formation of blood vessels, thereby promoting tumor growth. In non-small cell lung cancer (NSCLC) with EGFR mutation, EGFR activation can promote tumor growth by promoting VEGF upregulation through a hypoxia-independent mechanism. The upregulation of VEGF can make tumor cells resistant to EGFR inhibitors. In addition, the expression of the VEGF signal is also affected by other factors. Therefore, the use of a single EGFR inhibitor cannot completely inhibit the expression of the VEGF signal. In order to overcome this problem, the combination of VEGF inhibitors and EGFR inhibitors has become the method of choice. Dual inhibition can not only overcome the resistance of tumor cells to EGFR inhibitors, but also significantly increase the progression-free survival time of patients with NSCLC. The present review discusses the associations between the EGFR and VEGF pathways, and the characteristics of dual inhibition of the EGFR-VEGF pathway. D.A. Spandidos 2023-01-03 /pmc/articles/PMC9851127/ /pubmed/36601768 http://dx.doi.org/10.3892/ijo.2023.5474 Text en Copyright: © Wang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Wang, Qian Zeng, Anqi Zhu, Min Song, Linjiang Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) |
title | Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) |
title_full | Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) |
title_fullStr | Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) |
title_full_unstemmed | Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) |
title_short | Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review) |
title_sort | dual inhibition of egfr-vegf: an effective approach to the treatment of advanced non-small cell lung cancer with egfr mutation (review) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851127/ https://www.ncbi.nlm.nih.gov/pubmed/36601768 http://dx.doi.org/10.3892/ijo.2023.5474 |
work_keys_str_mv | AT wangqian dualinhibitionofegfrvegfaneffectiveapproachtothetreatmentofadvancednonsmallcelllungcancerwithegfrmutationreview AT zenganqi dualinhibitionofegfrvegfaneffectiveapproachtothetreatmentofadvancednonsmallcelllungcancerwithegfrmutationreview AT zhumin dualinhibitionofegfrvegfaneffectiveapproachtothetreatmentofadvancednonsmallcelllungcancerwithegfrmutationreview AT songlinjiang dualinhibitionofegfrvegfaneffectiveapproachtothetreatmentofadvancednonsmallcelllungcancerwithegfrmutationreview |